News
Novo Nordisk Shares Rise
Digest more
The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease.
Copenhagen-listed shares in pharmaceuticals giant Novo Nordisk rose nearly 4% on Monday morning, after the company announced ...
Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise ...
It seems to be holding off on price adjustments demanded by President Trump.
Eli Lilly's pricing strategy for GLP-1 drugs is expected to have minimal margin impact, with BofA reaffirming a $900 price ...
Zacks Investment Research on MSN2d
Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?
Novo Nordisk NVO recently underwent a major leadership transition, as Lars Fruergaard Jørgensen stepped down as CEO on Aug. 7 ...
Novo Nordisk's growth in diabetes and obesity care makes it a strong buy. Click here for a full investment analysis of NVO ...
While Novo Nordisk say they're fighting against stigma, critics say they could be promoting prescription drugs under the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback